Proposition - PharmXpert Academy
Proposition - PharmXpert Academy
Proposition - PharmXpert Academy
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
The Korean Pharmaceutical Company List 323<br />
2. Main Products Information<br />
No.<br />
Classification<br />
Section<br />
(Bio,<br />
Synthesis)<br />
The Name of<br />
Products<br />
Main<br />
Ingredient<br />
Use<br />
(Indications)<br />
Formulation<br />
The Date<br />
of Sales<br />
Expected<br />
Exporting<br />
Countries<br />
Etc.<br />
1<br />
Functional<br />
Food<br />
Bio<br />
Ob-X Dietary<br />
Fiber<br />
natural<br />
extracts<br />
Anti-obesity<br />
tablet<br />
May,<br />
2006<br />
USA,<br />
Europe,<br />
Asia<br />
3. R&D Figures<br />
No<br />
1<br />
Classification<br />
Functional<br />
Food<br />
Section<br />
(Bio,<br />
Synthesis)<br />
The Name of<br />
Technology<br />
Main<br />
Ingredient<br />
Bio Anti-obesity herbal<br />
extract<br />
2 Drug Bio Anti-obesity<br />
3 Drug Bio<br />
4 Drug Bio<br />
5 Drug Bio<br />
Ocular<br />
Therapeutics<br />
Anti-<br />
Periodontitis<br />
Antimetastasis<br />
6 Drug Synthesis Radiotherapy<br />
(sensitizer)<br />
7 Drug Bio<br />
8 Drug Bio<br />
Antiangiogenesis<br />
Antiangiogenesis<br />
Active<br />
fraction<br />
from herbal<br />
extract<br />
herbal<br />
extract<br />
herbal<br />
extract<br />
herbal<br />
extract<br />
organic<br />
compound<br />
Recombinant<br />
Protein<br />
Recombinant<br />
Protein<br />
Use<br />
(Indications)<br />
visceral fat<br />
reduction<br />
visceral fat<br />
reduction<br />
The Duration<br />
of<br />
Development<br />
The Stage of<br />
Development<br />
2000-2008 clinical prep.<br />
2000-2009<br />
clinical<br />
phase Ⅱ<br />
DR & AMD 2000-2009 pre-clinical<br />
Periodontal<br />
disease<br />
Anti-cancer 2000-2009 pre-clinical<br />
Radiotherapy<br />
use<br />
Anti-angioge<br />
nesis<br />
Future Plan<br />
FDA<br />
approval<br />
with health<br />
claim (2008)<br />
Complete<br />
clinical trials<br />
Ⅱ & ⅡI<br />
(2009)<br />
Expected<br />
Licensing<br />
(Domestic,<br />
Oversea)<br />
Domestic<br />
& Oversea<br />
Domestic<br />
& Oversea<br />
Complete<br />
pre-clinical & Domestic<br />
Licensing & Oversea<br />
(2008)<br />
Complete<br />
2000-2009 pre-clinical<br />
pre-clinical & Domestic<br />
Licensing & Oversea<br />
(2008)<br />
pre-clinical<br />
completion & Domestic<br />
licensing & Oversea<br />
(2009)<br />
Complete<br />
2000-2009 pre-clinical<br />
pre-clinical & Domestic<br />
Licensing & Oversea<br />
(2010)<br />
Complete<br />
2000-2010 pre-clinical<br />
pre-clinical & Domestic<br />
Licensing & Oversea<br />
(2010)<br />
Complete<br />
pre-clinical &<br />
Oversea<br />
Licensing<br />
(2010)<br />
Anti-cancer 2001-2010 pre-clinical
Change language